New data from a study presented at the 47th Annual Meeting of the European Association for the Study of Diabetes
(EASD) demonstrated that 102 patients who switched from oral therapy with sitagliptin to once-daily injectable therapy with Victoza® had an increase in overall treatment satisfaction.
Switching from oral therapy with sitagliptin to injectable therapy with Victoza® (both combined with metformin) resulted in further reductions in HbA1c and body weight and also increases overall treatment satisfaction.
Treatment satisfaction was evaluated using the Diabetes Treatment Satisfaction Questionnaire (DTSQ) at 52 and 78 weeks to assess the impact of switching from an oral therapy to an injectable one.
Patients who switched to Victoza® had an increase in overall treatment satisfaction, which was largely driven by patients who responded that they would ‘recommend’ and ‘continue’ their present treatment with Victoza®.
The once-daily injectable therapy with Victoza® was also ranked by patients as equally convenient and flexible as the oral therapy with sitagliptin.
“Patient satisfaction is becoming an increasingly more important factor when decisions about a treatment regimen are being made,” said Melanie Davies, Professor of Diabetes Medicine at the University of Leicester, UK.
“The results seen in this study are most likely attributed to the improved treatment efficacy and the weight loss associated with Victoza®, which further demonstrates the value of the drug.”